Gsk (GSK) Amortization - Intangibles (2013 - 2014)
Gsk (GSK) posted quarterly Amortization - Intangibles of $34.9 million for Q4 2014, down 25.76% year-over-year from $47.0 million in Q4 2013, and down 25.76% quarter-over-quarter from $47.0 million in Q4 2013.
Gsk (GSK) Amortization - Intangibles (2013 - 2014) Analysis & Trends
Gsk's Amortization - Intangibles history runs 2 years deep, the most recent figure standing at $34.9 million for Q4 2014.
- In Q4 2014, Amortization - Intangibles fell 25.76% year-over-year to $34.9 million; the TTM figure through Dec 2014 stood at $34.9 million (down 25.76% YoY), while the FY2014 annual figure was $34.9 million, down 25.76% from the prior year.
- Amortization - Intangibles for Q4 2014 stood at $34.9 million, down from $47.0 million in the prior quarter.
- The five-year high for Amortization - Intangibles was $47.0 million in Q4 2013, with the low at $34.9 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 34.86 Mn |
| Dec 31, 2013 | 46.95 Mn |